Interleukin 5 Synthesis by Eosinophils: Association with Granules and Immunoglobulin-dependent Secretion

By Sylvain Dubucquoi,* Pierre Desreumaux,*, Anne Janin,† Olivier Klein, Anne Janin, Olivier Klein, Michel Goldman, Jan Tavernier, André Capron,* and Monique Capron*

From the *Centre d'Immunologie et de Biologie Parasitaire, Institut Pasteur, 59019 Lille, France; †Anatomie et Pathologie, Hôpital Calmette, Centre Hospitalier Régional Universitaire (CHRU), 59000 Lille, France; ‡Service de Gastroentérologie, Hôpital Huriez, CHRU, 59000 Lille, France; §Département d'Immunologie, Hôpital Erasme, B1070 Bruxelles, Belgium; and ¶Roche Research Gent, B9000 Gent, Belgium

Summary

Interleukin 5 (IL-5) is the main factor that promotes the terminal differentiation of eosinophil progenitors (as indicated by colony formation assays), and enhances the effector capacity of mature eosinophils. IL-5 is produced by T lymphocytes, CD4+CD8− and mast cells and recently, messenger (m)RNA of this cytokine has been identified in eosinophils from patients with coeliac disease, asthma, or eosinophilic heart diseases. In this study, IL-5 mRNA and immunoreactive IL-5 protein were detected in tissue and blood eosinophils from patients with eosinophilic cystitis or hypereosinophilic syndromes but not in Crohn’s disease. By electron microscopy associated to immunogold staining, immunoreactive IL-5 was identified in eosinophilic granules. After stimulation with IgA-, IgE-, or IgG-immune complexes, blood eosinophils were shown, by immunocytochemistry and by enzyme-linked immunosorbent assay, to secrete IL-5. These observations demonstrate that eosinophils, under physiological stimulation, can release significant amounts of IL-5, which may contribute to local eosinophil recruitment and activation.

T

lymphocytes play a central role in eosinophil production, differentiation, and function through the release of soluble mediators. A number of cytokines with selective action on eosinophils has been cloned and sequenced. Among those, IL-5 is the main factor that promotes the terminal differentiation of the committed eosinophil precursors (1) and that enhances the effector capacity of mature eosinophils (2). Whereas IL-5 production by T cells has been well documented, mRNA for IL-5 also has been identified in mast cells and recently, messenger (m)RNA of this cytokine has been identified in eosinophils from patients with coeliac disease, asthma, or eosinophilic heart diseases. In this study, IL-5 mRNA and immunoreactive IL-5 protein were detected in tissue and blood eosinophils from patients with eosinophilic cystitis or hypereosinophilic syndromes but not in Crohn’s disease. By electron microscopy associated to immunogold staining, immunoreactive IL-5 was identified in eosinophilic granules. After stimulation with IgA-, IgE-, or IgG-immune complexes, blood eosinophils were shown, by immunocytochemistry and by enzyme-linked immunosorbent assay, to secrete IL-5. These observations demonstrate that eosinophils, under physiological stimulation, can release significant amounts of IL-5, which may contribute to local eosinophil recruitment and activation.

Materials and Methods

Eosinophils. Patients with a massive eosinophil infiltration (>30%) were selected. Bladder specimens were taken from a 47-yr-old woman who had presented several episodes of severe cystitis. Peripheral eosinophil counts were 840/mm³. Before treatment, histological examination revealed an eosinophilic cystitis. Four patients with Crohn’s disease were selected for the presence of numerous eosinophils infiltrating intestinal lesions (between 20 and 40% of the infiltrating cells), whereas blood eosinophil counts were normal.

Peripheral eosinophils were purified from the blood of six patients fulfilling the diagnostic criteria for idiopathic hypereosinophilic syndrome (HES): persistent eosinophilia (>1.5 × 10⁹/liter) for at
leasts 6 mo, multivisceral lesions, and absence of any recognized cause of eosinophilia. The mean blood eosinophil counts were 2.8 x 10^9/liter with SD 1.4. By using discontinuous metrizamide gradients, hypodense eosinophils, which sediment in the lightest density, were isolated (7). After washing with HBSS, the degree of purity (90-99%) was evaluated on cytocentrifuged preparations stained with Giemsa. After centrifugation, eosinophils were re-suspended in HBSS culture medium alone, without FCS, at a concentration of 10^6 cells/ml.

In Situ Hybridization. Bladder and intestinal specimens were immediately fixed in paraformaldehyde 4% in cacodylate buffer and embedded in paraffin. In situ hybridization was performed as previously described (4). Briefly, the cDNA for human IL-5 was subcloned into the Blue Script vector by standard techniques. Linearized plasmid was used as the template for the synthesis in vitro of a 3^S-labeled RNA probe (Amersham-Pharmacia, Les Ulis, France) complementary to the cellular IL-5 mRNA (antisense probe). RNA was also transcribed in the opposite direction and used as a negative control (sense probe). Antisense or sense probes (4,150 cpm/mm^2) were hybridized with bladder and intestinal samples as previously described (4). To inhibit nonspecific binding of 3^S, tissues were acetylated in triethanolamine 0.1 M, then in acetic anhydride 0.25% triethanolamine for 10 min before hybridization. Further, to avoid nonspecific binding to eosinophils, prehybridization was carried out with a solution containing a nonradioabeled S-UTP irrelevant probe for at least 2 h at 42°C, dithiothreitol (DTT) was added to the hybridization buffer, and RNase A was used for posthybridization washings. After development of the emulsion, tissue sections were then stained with May Grünwald Giemsa for examination by light microscopy.

Immunohistochemistry. To detect the presence of immunoreactive IL-5 in eosinophils, tissue paraffin sections or cytocentrifuged preparations of purified blood eosinophils were incubated with a mouse mAb (IgG1 isotype) directed against human IL-5. This mAb (SA5) has a neutralizing effect on human IL-5, did not crossreact with mouse IL-5, and has been purified on protein A-Sepharose (Van der Heyden, J., T. Tuypens, R. Devos, G. Plaetinck, Y. Guisez, and J. Tavernier, manuscript in preparation). Bladder or intestinal sections and cytocentrifuged preparations were washed in Tris-buffered saline (TBS), and anti-IL-5 mAb was added at a final concentration of 10^6 cells/ml. After incubation for 45 min at room temperature, slides were briefly washed in TBS, and enzymatic complex, alkaline phosphatase anti-alkaline phosphatase (APAAP; Dako, Glostrup, Denmark) was added at 1:50 dilution, and developed with NBT-BCIP substrate and neofuscin (Sigma Chemical Co., St. Louis, MO) as previously described (8). As control, a mAb of the same isotype but with a different specificity (anti-Echinococcus granulosus) was used with the same conditions.

Immunogold Staining. Bladder specimens were fixed in glutaraldehyde 2% in cacodylate buffer, dehydrated, and embedded at ~35°C in Lowicryl K4M. Lowicryl sections were obtained as previously described (9). In brief, after saturation with heat-inactivated normal rabbit serum, sections were incubated overnight at 4°C with anti-human IL-5 mAb at 50 µg/ml and diluted in TBS containing OVA (TBS-O). After washing with TBS-O and TBS, sections were transferred on 15 nm gold-conjugated rabbit anti-mouse IgG solution (diluted 1:30; Janssen Life Science Division, Beerse, Belgium). After a 1-h incubation at room temperature, grids were washed with TBS and distilled water successively. Lowicryl sections were stained with uranyl acetate and lead citrate. As controls, two mAbs of the same isotype were used in the same conditions: EG2, which recognizes the secreted form of eosinophil cationic protein (ECP) (kindly given by Dr. P. C. Tai, St. George Hospital Medical School, London, UK), was used as positive control, and anti-IgA mAb (Immunotech, Marseille Luminy, France) was used as a negative control. The observations were made at 60 kV with a Zeiss EM 10 electron microscope.

Eosinophil Activation. Highly purified eosinophils (>95% purity) from patients with hypereosinophilic syndromes were incubated in HBSS without serum for 24 h at 37°C and 5% CO2 with recombinant human IL-3 (kindly donated by Sandoz Ltd., Basel, Switzerland) and recombinant human GM-CSF, a generous gift of Dr. J. Banchereau (Schering Plough, Dardilly, France) at a final concentration of 10^-9 M.

Highly purified eosinophils from the six HES patients were also incubated with serum IgA, secretory IgA (both purchased from Sigma Chemical Co.) and myeloma IgE protein (PS myeloma; a kind gift of Dr. H. L. Spiegelberg, The Scripps Research Institute, La Jolla, CA), or with human IgG (Sigma Chemical Co.) at a final concentration of 15 µg/ml in HBSS without serum. After a 1-h incubation at +4°C, and without washing, eosinophils were then stimulated at 37°C and 5% CO2 with the corresponding anti-IgA, anti-IgE, or anti-IgG mAb (Immunotech) at a concentration of 20 µg/ml for a period of time varying between 15 min and 18 h.

The experiments were stopped by centrifugation of the tubes at 500 g for 10 min at 4°C. Supernatants were collected and frozen at -20°C until the ELISA could be performed. The cell pellets were re-suspended at a concentration of 0.8 x 10^6 cells/ml of HBSS and loaded onto gelatin-coated slides (0.8 x 10^6 cells/slide) by cytocentrifugation. The cytoperparates were immediately fixed in sterile acetone for 10 min and stored until analyzed for the presence of immunoreactive IL-5 by immunocytochemistry.

Measurement of IL-5 in Supernatants. IL-5 levels were determined by ELISA as previously described (11). Briefly, serial dilutions of culture supernatants were incubated for two h at room temperature in microwell modules (Maxisorps; Nunc, Roskilde, Denmark) coated with 0.5 µg/ml of the H30 rat anti-human IL-5 mAb IgG2b (provided by Dr. J. Van der Heyden, Roche Research). After washing, 0.1 µg of a mouse monoclonal anti-human IL-5 mAb IgG1 (kindly provided by Glaxo Group Research Ltd., Greenford, Middlesex, UK) was added. Finally, the binding of the latter mAb was revealed by horseradish peroxidase–conjugated rat anti-mouse IgG1 mAb (LO MGI-5; Experimental Immunology Unit, Université Catholique de Louvain, Brussels, Belgium) followed by the appropriate substrate solution. Optical densities at 450 nm were converted in pg/ml of IL-5 using a standard curve constructed with the recombinant human IL-5 kindly provided by Roche Research.

Results and Discussion

Presence of IL-5 mRNA. When bladder sections performed in a patient with eosinophilic cystitis were submitted to in situ hybridization, a strong positive signal was observed on numerous cells with the radiolabeled IL-5 antisense RNA probe (Fig. 1A). Intestinal sections with massive eosinophilic infiltration, performed in the four patients with Crohn's disease, were submitted to the same procedure. In contrast with bladder sections of the patient with eosinophilic cystitis, only few cells showed a positive signal (Fig. 1C). No signal was observed with the respective control sense probes (Fig. 1, B and D).

Immunostaining with Anti-human IL-5 mAb To further characterize the cell population involved in the synthesis of
immunoreactive IL-5, immunostaining of bladder sections with anti-human IL-5 mAb was performed. Using the APAAP procedure, typical binucleated cells were positively stained (Fig. 1 E), whereas no staining was observed with the isotype control antibody (Fig. 1 F). Eosinophils were the only cell type with a polyllobulated nucleus in these sections. A similar procedure performed on intestinal sections from patients with Crohn's disease revealed a positive immunostaining of mononuclear cells only (data not shown).

Highly purified blood eosinophils could also be positively stained with anti-IL-5, but only after priming with IL-3 and GM-CSF (Fig. 2 A), whereas no staining was observed with medium alone or on resting eosinophils (Fig. 2 B). These results indicate that tissue eosinophils present in eosinophilic cystitis as well as ex vivo activated blood eosinophils could translate IL-5 mRNA, whereas eosinophils in Crohn's disease could not, confirming the results of in situ hybridization. These findings confirm and extend the recently published results (4-6) showing that eosinophils can transcribe IL-5 mRNA in coeliac disease, HES, asthma, or eosinophilic heart disease. However, they suggest that IL-5 expression by eosinophils is not observed in all diseases associated with massive eosinophilic infiltration.

A careful examination of eosinophils stained with the anti-IL-5 mAb revealed a heterogeneous labeling of the cytoplasm (Fig. 2 A), differing from the previously described immunostaining for GM-CSF (12) but resembling the intracytoplasmic staining for IL-8 (13). These findings led us to explore the subcellular localization of IL-5 in eosinophils.

**Association of IL-5 with Eosinophil Granules.** To localize IL-5...
in eosinophils, immunogoldstaining with anti-IL-5 mAb revealed by means of gold-labeled anti-mouse rabbit antibodies and electron microscopy was performed on bladder sections embedded in Lowicryl. As positive control, EG2, a mAb which binds to ECP, located in granule matrix, was used. As shown in Fig. 3 A, the binding of anti-IL-5 mAb was concentrated to granule matrix, similarly to EG2 staining (Fig. 3 C). All examined eosinophils, and more than 70%
of the granules were stained with the anti-human IL-5 mAb. No staining was obtained with the anti-IgA mAb used as negative control (Fig. 3 B). Eosinophils could therefore translate IL-5 mRNA and store the IL-5 protein in their granules. No precise identification of the localization of GM-CSF was given in the published study (12). However, the staining of eosinophil cytoplasm by the respective antibody suggested that GM-CSF localization or storage differed from IL-5. A similar granule localization has been reported for TNF-α in mast cells (14). Upon activation, eosinophils may release IL-5 more rapidly in the extracellular space, upon degranulation, without neosynthesis.

**Synthesis and Secretion of IL-5 after Eosinophil Activation.** Since immobilized or cross-linked IgA is able to induce eosinophil degranulation (15, 16), we looked further at whether IgA–anti-IgA immune complexes could lead to IL-5 secretion. A kinetic study revealed that after activation of blood eosinophils with IgA immune complexes for 15 min at 37°C, a positive intracytoplasmic staining with anti-IL-5 mAb was observed (Fig. 2 C). After 2 h of incubation, IL-5 staining was located on the periphery and the membrane of the majority of the cells, whereas few eosinophils still showed a cytoplasmic staining (Fig. 2 D). No staining could be observed after 18 h of incubation (Fig. 2 E). These results suggested that IL-5 could be secreted by eosinophils. To confirm this hypothesis, the secretion of IL-5 by purified blood eosinophils after activation with immune complexes, was investigated by measurement of IL-5 in supernatants.

The amounts of IL-5 were measured in the supernatants of highly purified eosinophils by the double sandwich ELISA procedure (Fig. 4). Significant amounts of IL-5 were measured in the supernatants of eosinophils after 18 h of activation with serum or secretory IgA. IL-5 could also be secreted after IgE- or IgG-dependent activation, but with important variations, according to the eosinophil donors.

Our results indicate that ex vivo activation of eosinophils with immune complexes, and principally IgA, consistently led to synthesis and secretion of the highest amounts of IL-5. They are in agreement with previous reports showing that IgA is the more potent stimulus for the release of granule proteins such as EDN (15), EPO, and ECP (16). Moreover, the localization of IL-5 associated with the role of insolubilized IgA in eosinophil degranulation might explain the detection of IL-5 in coeliac disease and eosinophilic cystitis where eosinophils are closely linked to IgA plasma cells (17, 18). In contrast, in coeliac disease with IgA deficiency, IL-5 was not detected in eosinophils (P. Desreumaux, personal communication) as well as in Crohn's disease, where IgM and IgG prevail (19).

In view of our results, we suggest that a short incubation with immune complexes induced IL-5 expression, whereas upon prolonged incubation, the secretion was initiated. Evidence for translation of IL-5 mRNA into immunoreactive IL-5 by eosinophils from patients with various diseases was obtained by immunostaining with a specific mAb to human IL-5. A kinetic study of IL-5 immunodetection after activation of eosinophils with IgA immune complexes in vitro confirmed the synthesis of IL-5 protein by eosinophils and ruled out a possible phagocytosis of exogenous IL-5. In addition, the identification of picogram amounts of IL-5 in the supernatants of highly purified eosinophils only after activation, provides evidence to support the fact that eosinophils can synthesize, store, and secrete IL-5.

Activated T cells remain the principal cellular source of IL-5, but the synthesis and secretion of IL-5 by eosinophils may provide an important autocrine pathway that is involved in local eosinophil recruitment and activation. The synthesis of their own activating factors might explain the chronicity of lesions in diseases associated with massive eosinophilic infiltration.

---

We would like to thank Dr. L. Prin and J. F. Colombel for access to patients. We are also grateful to S. Loiseau and A. Crusiaux, and to C. Drolez and M. F. Massard for help in the preparation of the manuscript.

This work was supported by Unité mixte Institut National de la Santé et de la Recherche Médicale U 167-Centre National de la Recherche Scientifique 624 and by Centre Hospitalier Régionnel Universitaire Lille. (Contrat 93-02).

Address correspondence to Dr. Monique Capron, CIBP, Institut Pasteur, 1, rue du Prof. A. Calmette, BP 245, 59019 Lille Cédex, France.

Received for publication 28 July 1993 and in revised form 16 November 1993.

**References**

1. Yamaguchi, Y., T. Suda, J. Suda, M. Eguchi, Y. Miura, N. Harada, A. Tominaga, and K. Takatsu. 1988. Purified interleukin 5 supports the terminal differentiation and proliferation of murine eosinophil precursors. *J. Exp. Med.* 167:43.

2. Lopez, A.F., C.J. Sanderson, J.R. Gamble, H.D. Campbell, I.G. Young, and M.A. Vadas. 1988. Recombinant human interleukin 5 is a selective activator of human eosinophil function. *J. Exp. Med.* 167:219.

3. Plaut, M., J.H. Pierce, C.J. Watson, J. Hanley-Hyde, R.P. Nordan, and W.E. Paul. 1989. Mast cell lines produce lymphokines in response to cross-linkage of FcεRI or to calcium ionophores. *Nature (Lond.)* 339:64.
4. Desreumaux, P., A. Janin, J.F. Colombel, L. Prin, J. Plumas, D. Emilie, G. Torpier, A. Capron, and M. Capron. 1992. Interleukin 5 messenger RNA expression by eosinophils in the intestinal mucosa of patients with coeliac disease. J. Exp. Med. 175:293.

5. Broide, D.H., M.M. Paine, and G.S. Firestein. 1992. Eosinophils express interleukin 5 and granulocyte macrophage-colony stimulating factor mRNA at sites of allergic inflammation in asthma. J. Clin. Invest. 90:1414.

6. Desreumaux, P., A. Janin, S. Dubucquoi, M.C. Copin, G. Torpier, A. Capron, M. Capron, and L. Prin. 1993. Synthesis of interleukin 5 by activated eosinophils in patients with eosinophilic heart diseases. Blood. 82:1553.

7. Prin, L., M. Capron, A.B. Tonnel, O. Bletry, and A. Capron. 1983. Heterogeneity of human blood eosinophils: variability in cell density and cytotoxic ability in relation to the level and the origin of the hypereosinophilia. Int. Arch. Allergy Appl. Immunol. 72:336.

8. Mason, D.Y., and R. Sammons. 1978. Alkaline phosphatase and peroxidase for double immunoenzymatic labelling of cellular contents. J. Clin. Pathol. 31:454.

9. Torpier, G., J.F. Colombel, C. Mathieu-Chandelier, M. Capron, J.P. Dessaint, A. Cortot, J.C. Paris, and A. Capron. 1988. Eosinophilic gastroenteritis: ultrastructural evidence for a selective release of eosinophil major basic protein. Clin. Exp. Immunol. 74:404.

10. Tai, P.C., C.J.F. Spry, C. Peterson, P. Venge, and I. Olsson. 1984. Monoclonal antibodies distinguish between storage and secreted forms of eosinophil cationic protein. Nature (Lond.). 308:182.

11. Schandené, L., A. Ferster, F. Mascart-Lemone, A. Crusiaux, C. Gérard, A. Marchant, M. Lybin, T. Velu, E. Sariban, and M. Goldman. 1993. T-helper type 2-like cells and therapeutic effects of interferon-γ in combined immunodeficiency with hypereosinophilia (Ommen's syndrome). Eur. J. Immunol. 23:56.

12. Moqbel, R., Q. Hamid, S. Ying, J. Barkans, A. Hartnell, A. Tsicopoulos, A.J. Wardlaw, and A.B. Kay. 1991. Expression of mRNA and immunoreactivity for the granulocyte macrophage colony-stimulating factor in activated human eosinophils. J. Exp. Med. 174:749.

13. Braun, K.R., M. Francini, F. Erard, S. Rihs, J.M. De Vries, K. Blaser, T.T. Hansel, and C. Walker. 1993. Human peripheral blood eosinophils produce and release interleukin-8 on stimulation with calcium ionophore. Eur. J. Immunol. 23:956.

14. Gordon, J.R., and S.J. Galli. 1991. Release of both preformed and newly synthesized tumor necrosis factor α (TNF-α)/cachectin by mouse mast cells stimulated via the FcεRI. A mechanism for the sustained action of mast cell-derived TNF-α during IgE-dependent biological responses. J. Exp. Med. 174:103.

15. Abu Ghazaleh, R., T. Fusisawa, J. Mestecky, A. Kyle, and G.J. Gleich. 1989. IgA-induced eosinophil degranulation. J. Immunol. 142:2393.

16. Tomassini, M., A. Tsicopoulos, E. Van der Vorst, J.P. Kusnierz, J.P. Papin, A. Capron, and M. Capron. 1991. Release of granule protein by eosinophils from allergic and non allergic patients with hypereosinophilia on immunoglobulin-dependent activation. J. Allergy Clin. Immunol. 88:365.

17. Brandtzæg, P., T.S. Halstensen, and K. Kett. 1989. Immunobiology and immunopathology of human gut mucosa: humoral immunity and intra-epithelial lymphocytes. Gastroenterol. 97:1562.

18. Rubin, L., and M.B. Pincus. 1974. Eosinophilic cystitis: the relationship of allergy to eosinophilic cystitis and the pathophysiology of eosinophilia. J. Urol. 112:457.

19. Schreiber, S., A. Readler, W.F. Stenson, and R.P. MacDermott. 1992. The role of the mucosal immune system in inflammatory bowel disease. Gastroenterol. Clin. North Am. 21:451.